ClinicalTrials.gg
RecruitingNCT07135882PRIME-LungUpdated Oct 23, 2026

Primary Radiotherapy In MEtastatic Lung Cancer

A Phase 3 interventional study of Radiotherapy followed by chemotherapy and Standard of Care (SOC) in Carcinoma, Non-Small-Cell Lung (NSCLC), sponsored by Trans Tasman Radiation Oncology Group. Recruiting at 6 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Trans Tasman Radiation Oncology Group · Phase 3, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Carcinoma with a site in Australia — 14 open to participants now, 22 under way, 12 of them phase 3. Carcinoma · Australia.

Planned enrollment
21st of 48
420 · median 263
Started
2026
with 4 others
Phase 3
27 of 48
6 open now
Primary completion
2030-12
later than 18 of 21 live
Registered
43rd of 48
by date
Lead sponsor
2 of 48
Trans Tasman Radiation Oncology Group

Among the 48 studies in Carcinoma with a site in Australia, this one is the 21st largest by planned enrollment, is one of 5 that started in 2026, is one of 27 in phase 3, reaches primary completion later than 18 of the 21 other live ones, and was the 43rd registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

14 of the 48 studies in Carcinoma with a site in Australia are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Carcinoma with a site in Australia, or all of them as a file.
02

Study summary

Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.

Read the detailed description

Lung cancer is the leading cause of cancer-related death and is the second most common cancer in both men and women in Australia, and globally. Non-small cell lung cancer (NSCLC) accounts for 85% of cases. Almost half of the cases present with metastatic disease, in whom average survival is less than two years despite recent advances with immunotherapy. Drug therapies alone have not been able to overcome this ceiling in survival.

The primary lung tumour is a source of ongoing seeding of new metastatic (secondary) sites of disease, and we will test whether eradication of the primary tumour through non-invasive radiotherapy will limit metastases, enhance the effect of drug therapy and ultimately improve patient outcomes. Radiotherapy is a rapidly translatable solution to address this unmet need.

In the Primary Radiotherapy In MEtastatic Lung cancer (PRIME-Lung) trial, patients with metastatic NSCLC will receive standard of care systemic therapy with or without radiotherapy to the primary lung tumour. We hypothesise that radiotherapy will improve overall survival above standard of care drug therapy. PRIME-Lung is a randomised controlled phase III clinical trial and will provide a definitive answer to this critical issue.

The study team includes representation from radiation and medical oncology, physics, respiratory medicine, biostatistics, health economics and quality of life experts. The PRIME-Lung trial was designed in consultation with consumers to ensure acceptability and applicability to this area of unmet need. Furthermore, to accelerate rollout and accessibility, the trial will build on the existing AURORA lung cancer registry, leveraging the registry's established data management processes and over 25 already active sites. As radiotherapy is a pillar of oncology and widely available, upon successful completion of this trial we expect rapid translation into the community and widespread adoption of the trial results.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung (NSCLC)

Keywords

  • Non-Small Cell Lung Cancer
  • Lung Neoplasms
  • Lung Cancer
  • Clinical reseach
  • Radiation Therapy
  • Advanced lung cancer
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed (stage IV) NSCLC, not amenable to curative surgery or curative radiotherapy
  • or cytologically documented NSCLC
  • Primary suitable for radiotherapy and not requiring immediate palliative thoracic irradiation
  • Investigator deemed appropriate for SoC systemic therapy
  • Metastases in up to 3 organ systems

Exclusion criteria

Exclusion Criteria:

  • Medically unfit for systemic therapy
  • EGFR/ALK/ROS1 mutation positive or actionable driver mutation with intention to use available targeted drug therapy
  • Has had previous thoracic radiotherapy of > 36Gy within the 6 months prior to randomisation.
  • Has been diagnosed and/or treated additional within 2 years prior to randomisation with the exception of: Curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively treated early-stage cervical cancer, breast cancer or prostate cancer with no evidence of active disease and not on active therapy. Other exceptions may be considered following consultation with the principal investigator
  • Has a history of (non-infectious) pneumonitis or current pneumonitis that requires active with a dose equivalent of prednisolone > 10mg/d.
  • A known diagnosis of fibrotic interstitial lung disease
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Uncontrolled not amenable to debulking surgery or stereotactic radiotherapy
  • Has an active disease that has required systemic treatment within last year (i.e. with use of disease modifying agents, corticosteroids or drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Active comparator
    Arm1: Standard of Care

    Standard of care systemic chemotherapy

    Drug: Standard of Care (SOC)

  • Active comparator
    Arm 2: Standard of Care + Radiotherapy to primary

    Primary irradiation followed by standard of care systemic chemotherapy

    Combination Product: Radiotherapy followed by chemotherapy

Interventions

  • Combination productRadiotherapy followed by chemotherapy

    Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens. Radiotherapy Techniques: * Highly conformal techniques (IMRT/VMAT) * High-precision techniques are allowed for non-centrally located primaries Radiotherapy Dose: \- Several fractionation schedules allowed; minimum biological effective dose approximating 50Gy (α/β ratio = 10); 50Gy in 20 fractions, 40Gy in 15 fractions, and 35Gy in 5 fractions

    Also known as: Standard of Care, Chemotherapy, Immunotherapy

  • DrugStandard of Care (SOC)

    Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens.

    Also known as: chemotherapy, immunotherapy

06

What researchers measure

Primary outcomes

  1. Overall survival

    To assess the overall survival of patients receiving SoC systemic therapy with or without radiotherapy to the primary lung tumour

    Time frame: 5 years after the last participant was recruited

Secondary outcomes

  1. Thoracic toxicity as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    To assess the safety of the addition of radiotherapy by describing thoracic toxicities of interest during the follow up period in each arm (as assessed by NCI CTCAE v5.0) and to describe the discontinuation rate of systemic therapy and reasons for discontinuation

    Time frame: 2-years after the last participant has been randomised

  2. Progression Free Survival

    To assess the likelihood of progression, or death, in each arm

    Time frame: 2-years after the last participant has been randomised

  3. Cancer specific survival

    To assess death from cancer-related causes in each arm

    Time frame: 2-years after the last participant has been randomised

  4. Patient Reported Quality of Life (QoL) assessed using EORTC QLQ-C30 questionnaire

    To compare the effect of treatment on overall QOL, at each time point (baseline, 3, 6, 12, and 24 months) between trial arms, collected on European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) questionnaire.

    Time frame: 2-years after the last participant has been randomised

  5. Cost effectiveness of RT plus SoC compared with SoC alone with respect to the incremental cost per quality-adjusted life year (QALYs) gained

    Patient-specific costs associated with accessing care, particularly those associated with travel time for attendance, will be assessed based on questionnaires. QALYs, the combined impact of lung cancer and its treatment on survival and QoL, will be estimated by using the EORTC QLU-C10D (derived from the EORTC QLQ-C30) and EQ-5D-5L.

    Time frame: 2-years after the last participant has been randomised

07

Study locations

1 of 6 sites recruiting
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
    Not yet recruiting
  • ICON Cancer Centre - Gold Coast University Hospital
    Gold Coast, Queensland 4215, Australia
    Not yet recruiting
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
    Not yet recruiting
  • Ballarat Austin Radiation Oncology Centre (BAROC)
    Ballarat, Victoria 3350, Australia
    Not yet recruiting
  • Peter MacCallam Cancer Centre
    Melbourne, Victoria 3000, Australia
    Recruiting
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Australian data will be collected using established Lung Cancer registry (AURORA). The trial sponsor is not the custodian of this registry, therefore is able to confirm IPD data can be shared at this stage.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2030, 50 months later.

Of 35 phase 3 interventional studies under Carcinoma, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 82. This study's planned 50 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 22, 2025
StartEst.
Oct 30, 2026was Aug 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2036
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
4 sites added. 2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
Show 2 sites
  • ICON Cancer Centre - Gold Coast University Hospital · Gold Coast, Australiano status→Not yet recruiting
  • Peter MacCallam Cancer Centre · Melbourne, Australiano status→Recruiting
Show 4 added (4 Australia)
  • Blacktown Hospital · Blacktown, Australia
  • Royal Adelaide Hospital · Adelaide, Australia
  • Ballarat Austin Radiation Oncology Centre (BAROC) · Ballarat, Australia
  • Sir Charles Gairdner Hospital · Nedlands, Australia
across 2 updates, Oct 14, 2026 – Oct 23, 2026
Start date
Aug 25, 2026→Oct 30, 2026
Oct 14, 2026
Eligibility
1 inclusion criterion removed
What changed in the criteria
Inclusion criteria
  • RemovedEGFR/ALK/ROS1 Wild-type
Oct 14, 2026
Show all 2 updates
  1. Oct 23, 2026
    4 sites added
    Show 4 added (4 Australia)
    • Blacktown Hospital · Blacktown, Australia
    • Royal Adelaide Hospital · Adelaide, Australia
    • Ballarat Austin Radiation Oncology Centre (BAROC) · Ballarat, Australia
    • Sir Charles Gairdner Hospital · Nedlands, Australia
  2. Oct 14, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
    Show 2 sites
    • ICON Cancer Centre - Gold Coast University Hospital · Gold Coast, Australiano status→Not yet recruiting
    • Peter MacCallam Cancer Centre · Melbourne, Australiano status→Recruiting
    Start date Aug 25, 2026→Oct 30, 2026
    Eligibility 1 inclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • RemovedEGFR/ALK/ROS1 Wild-type
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135882
Lead sponsor
Trans Tasman Radiation Oncology Group
Collaborators
Thoracic Oncology Group of Australasia (TOGA)
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Oct 30, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Oct 23, 2026

Study contacts

PRIME-Lung CRA
Contact
primelung@trog.com.au
+61240143911
Shankar Siva
study chair · Peter MacCallum Cancer Centre, Australia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion